Saed Shawar

Saed Shawar

Auto-generated profile, based on publicly available information

Saed Shawar

Department of Kidney Transplant Surgery, Vanderbilt University, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
RRRajeev Raghavan
Rajeev Raghavan
SSSaed Shawar
Saed Shawar

7 December 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
OBOriol Bestard
Oriol Bestard
JAJoshua Augustine
Joshua Augustine
AWAlvin Wee
Alvin Wee
EPEmilio Poggio
Emilio Poggio
RMRoslyn B. Mannon
Roslyn B. Mannon
MDMichael J. Donovan
Michael J. Donovan
The objective of this study was to validate the performance of Tutivia, a peripheral blood gene expression signature, in predicting early acute rejection (AR) post-kidney transplant. Recipients of living or deceased donor kidney transplants were enrolled in a nonrandomized, prospective, global, and observational study (NCT04727788). The main outcome was validation of the area under the curve (AUC) of Tutivia vs serum creatinine at biopsy alone, or Tutivia + serum creatinine at biopsy. Of the 151 kidney transplant recipients, the mean cohort age was 53 years old, and 64% were male. There were 71% (107/151) surveillance/protocol biopsies and 29% (44/151) for-cause biopsies, with a 31% (47/151) overall rejection rate. Tutivia (AUC 0.69 [95% CI: 0.59-0.77]) and AUC of Tutivia + creatinine at biopsy (0.68 [95% CI: 0.59-0.77]) were greater than the AUC of creatinine at biopsy alone (0.51.4 [95% CI: 0.43-0.60]). Applying a model cut-off of 50 (scale 0-100) generated a high- and low-risk category for AR with a negative predictive value of 0.79 (95% CI: 0.71-0.86), a positive predictive value of 0.60 (95% CI: 0.45-0.74), and an odds ratio of 5.74 (95% CI: 2.63-12.54). Tutivia represents a validated noninvasive approach for clinicians to accurately predict early AR, beyond the current standard of care.

6 February 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NSNeeraj Singh
Neeraj Singh
PAPrince Mohan Anand
Prince Mohan Anand
GGGaurav Gupta
Gaurav Gupta
DSDeirdre Sawinski
Deirdre Sawinski
OFOren Fix
Oren Fix
RBRoy Bloom
Roy Bloom
Kidney transplant is not only the best treatment for patients with advanced kidney disease but it also reduces health care expenditure. The management of transplant patients is complex as they require special care by transplant nephrologists who have expertise in assessing transplant candidates, understand immunology and organ rejection, have familiarity with perioperative complications, and have the ability to manage the long-term effects of chronic immunosuppression. This skill set at the intersection of multiple disciplines necessitates additional training in Transplant Nephrology. Currently, there are more than 250,000 patients with a functioning kidney allograft and over 100,000 waitlisted patients awaiting kidney transplant, with a burgeoning number added to the kidney transplant wait list every year. In 2022, more than 40,000 patients were added to the kidney wait list and more than 25,000 received a kidney transplant. The Advancing American Kidney Health Initiative, passed in 2019, is aiming to double the number of kidney transplants by 2030 creating a need for additional transplant nephrologists to help care for them. Over the past decade, there has been a decline in the Nephrology—as well Transplant Nephrology—workforce due to a multitude of reasons. The American Society of Transplantation Kidney Pancreas Community of Practice created a workgroup to discuss the Transplant Nephrology workforce shortage. In this article, we discuss the scope of the problem and how the Accreditation Council for Graduate Medical Education recognition of Transplant Nephrology Fellowship could at least partly mitigate the Transplant Nephrology work force crisis.

30 September 2022 in Kidney Medicine
Verified
Journal Article
Open access
ACAlissar El Chediak
Alissar El Chediak
JTJefferson L. Triozzi
Jefferson L. Triozzi
HSHeidi Schaefer
Heidi Schaefer
SSSaed Shawar
Saed Shawar
Nocardiosis is a rare, life-threatening opportunistic infection caused by bacteria in the environment that predominantly affects immunocompromised patients. Nocardiosis most commonly involves the lungs but can disseminate to other organs. Disseminated nocardiosis, defined as Nocardia infection involving 2 or more organ systems, requires early detection and treatment because of high morbidity and mortality. We report 2 cases of disseminated nocardiosis with pulmonary and central nervous system involvement in kidney transplant recipients. Nocardiosis should be suspected in immunocompromised patients with fever and lung mass, although atypical presentations involving almost any organ can be seen. Solid organ transplant recipients are at greatest risk for Nocardia infection within the first 1 to 2 years after transplantation. However, the patients presented here developed disseminated nocardiosis several years after transplantation, which has important implications. Nocardiosis is treated with 2 to 6 weeks of empiric induction antibiotics, followed by 6 to 12 months of maintenance antibiotics based on antimicrobial susceptibility testing.

14 May 2026 in Kidney360
Verified
Journal Article
Open access
BCBeatrice P. Concepcion
Beatrice P. Concepcion
OBOriol Bestard
Oriol Bestard
MSMilagros Samaniego-Picota
Milagros Samaniego-Picota
RPRohini Prashar
Rohini Prashar
MAM. Javeed Ansari
M. Javeed Ansari
MDMichael J. Donovan
Michael J. Donovan
Key Points: Pretransplant early acute rejection risk stratification offers a novel approach to personalized immunosuppression management in patients who received a kidney transplant. Stratifying immunologic risk independent of donor characteristics may help guide immunosuppression management in patients who received a kidney transplant. The pretransplant risk assessment gene set reflects metabolic and immune pathways involved in T-cell– and antibody-mediated mechanisms of transplant rejection. Background: Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection (EAR). We developed and validated a next-generation sequencing assay targeting the pretransplant immunologic profile to predict EAR following kidney transplantation. Methods: This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected before transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pretransplant risk assessment (PTRA) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict EAR risk was clinically validated using 122 deceased donor kidney transplant recipients. Results: PTRA classified 31 of 122 participants (25%) as high risk and 91 (75%) as low risk. There were nine EAR events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for EAR at 60 days post-transplant yielded an area under the curve of 0.78 (95% confidence interval [CI], 64.4 to 91.5), P < 0.001. A cutoff of ≤45 was defined as low risk and >45 as high risk for EAR within 60 days post-transplant. Sensitivity was 0.67 (95% CI, 0.36 to 0.97), specificity 0.78 (95% CI, 0.70 to 0.86), positive predictive value 0.19 (95% CI, 0.05 to 0.33), and negative predictive value 0.97 (95% CI, 0.93 to 1.00). The odds ratio comparing patients identified as high versus low risk by PTRA was 7.04 (95% CI, 1.64 to 30.2), P = 0.009. Conclusions: This study validates the ability of PTRA to stratify kidney transplant recipients as high or low risk for EAR using a pretransplant transcriptomic profile, with implications for graft health and personalized treatment management.

28 March 2024 in Clinical Transplantation
Verified
Journal Article
Open access
ACAlissar El Chediak
Alissar El Chediak
SSSaed Shawar
Saed Shawar
MFMohammad K. Fallahzadeh
Mohammad K. Fallahzadeh
RFRachel Forbes
Rachel Forbes
HSHeidi M. Schaefer
Heidi M. Schaefer
DSDavid Shaffer
David Shaffer
Introduction: Data on long‐term outcomes following A2/A2B to B kidney transplants since the 2014 kidney allocation system (KAS) changes are few. The primary aim of this study is to report our 7‐year experience with A2/A2B to B kidney transplants and to compare post‐transplant outcomes of A2/A2B to a concurrent group of B to B kidney transplants. Additionally, the study evaluates the impact of pre‐transplant anti‐A1 titers on survival outcomes in A2/A2B transplants.Methods: This retrospective, single‐center analysis included all adults who received A2/A2B to B deceased donor kidney transplants from December 2014 to June 2021 compared to B to B recipients. The effects of pre‐transplant IgM/IgG titers, stratified as ≤1:8 and ≥1:16, on death‐censored, rejection‐free, and overall graft survival were tested.Results: Fifty‐three A2/A2B and 114 B to B adults were included with a median follow‐up time of 32 months. Overall graft survival, patient survival, and rejection‐free graft survival did not differ between the two groups. There were no differences between the groups’ overall kidney function values (p > .80) or their temporal trajectories (time by group interaction p > .11). Unadjusted death‐censored graft survival was lower in A2/A2B to B compared to B recipients (p = .03), but the effect was not significant (p = .195) after adjusting for any readmissions (p = .96), rejection episodes (p < .001) or BK infection (p = .76). We did not detect an effect of pre‐transplant titer group on death‐censored (p = .59), rejection‐free (p = .61), or overall graft survival (p = .26)Conclusions: A2/A2B to B kidney transplants have comparable overall patient and graft survival, rejection‐free graft survival, and longitudinal renal function compared to B to B transplants at our center. Allograft survival outcomes were not significantly different between patients with low and high pre‐transplant anti‐A1 IgM/IgG titers.